When is barrier function a relevant clinical consideration?
The importance of an effective physical and immune barrier at the site of host-microbiome interactions cannot be downplayed.
Research shows us that an impaired barrier leads to a greater burden of immunomodulating substances such as lipopolysaccharides (LPS) and food proteins entering the system. This has been linked to a plethora of conditions from mental, metabolic and immune to localised gastrointestinal conditions.
And when we talk about barriers, we must consider all mucosal barriers – gut, brain, oral, lung, vaginal…
Considering this, is there ever a time when barrier function isn’t relevant in clinical practice?
Our solution: Bio.Me™ Barrier
Our barrier-specific probiotic with human clinical research to back it up.
- 10 billion CFU multi-species probiotic containing key Bifidobacterium, Lactobacillus and Lactococcus strains
- Strains have been researched in vivo and in vitro
- Strains have been researched for their compatibility to be bottled together
- Human clinical trials using Bio.Me™ Barrier show significant results in mental health, liver cirrhosis and migraine
- Improves markers of intestinal barrier permeability
- Breaks down LPS
- Stimulates IL-10
- Non-histamine inducing
- Probioact technology ensures stability, survival and metabolic activity
- Doesn’t need to be refrigerated
- Dairy-free, vegetarian, gluten-free, stevia-free, GMP, GMO-free
- Available in 120g
- From 58p per dose